By allowing insurance companies to price plans based on biometric data (blood pressure, fitness), you create powerful financial incentives for people to improve their health. This moves beyond abstract advice and makes diet and exercise a direct factor in personal finance, driving real behavioral change.

TrueMed's model allows consumers to use tax-free HSA/FSA funds for preventative health measures like gym memberships and healthy food. By facilitating a "letter of medical necessity," it effectively reclassifies these lifestyle interventions as legitimate medical expenses, creating a financial incentive for prevention.

The core of value-based care is a business model where preventing adverse events like strokes is more profitable than treating them. This fundamental financial alignment, not just quality measures, drives organizations like Kaiser to invest in team-based care and proactive protocols, a reality that clinicians within the system may not even perceive.

General Catalyst's CEO highlights a core flaw in healthcare: insurance providers don't reimburse for longevity or preventative care because customers frequently switch plans, preventing insurers from capturing long-term ROI. The first company to solve this misalignment and make longevity "financeable" will unlock a massive market.

Widespread adoption of preventive health measures faces a major political hurdle. Politicians on four-year election cycles are incentivized to fund programs with immediate effects, rather than long-term prevention initiatives that may take 20-30 years to show results.

A $2,000 preventative injection like a PCSK9 inhibitor sounds expensive. However, its cost is likely justified when calculated against the massive societal and individual expense of future medical bills, plus the economic value of additional healthy, productive years.

Chronic illnesses like cancer, heart disease, and Alzheimer's typically develop over two decades before symptoms appear. This long "runway" is a massive, underutilized opportunity to identify high-risk individuals and intervene, yet medicine typically focuses on treatment only after a disease is established.

Treating obesity with drugs like Wegovy for a limited time, such as two years, is akin to only treating high cholesterol temporarily. This policy ignores the medical reality that obesity is a chronic disease requiring lifelong management, not a short-term condition.

As more people opt out of insurance, they may delay preventative care and rely on expensive emergency rooms when issues become critical. This uncompensated care inadvertently increases costs across the system, a problem the Affordable Care Act aimed to solve.